Artivion Inc. (AORT) PT Raised to $45 at Needham

Needham analyst Mike Matson raised the price target on Artivion Inc. (NYSE: AORT) to $45.00 (from $32.00) while maintaining a Buy rating.

The analyst comments "AORT's 2Q25 revenue and EBITDA beat consensus and AORT raised its 2025 revenue guidance and EBITDA guidance. Constant currency (CC) revenue growth improved to 14.6% in 2Q25 from 3.6% in 1Q25, driven by strong On-X and stent graft growth. Gross margin was up 10 bps Y/Y and EBITDA margin was up 290 bps Y/Y. In terms of key products, On-X was up 24% CC, stent grafts were up 22% CC, BioGlue was up 4% CC, and Preservation Services was up 3% CC. Geographically, North America grew 18% CC, Asia Pacific grew 15% CC and EMEA grew 10% CC. The AMDS launch is progressing well and AORT's growth is accelerating. AORT is also making further progress with its pipeline including NEXUS and Arcevo. We reiterate our Buy rating and raise our price target to $45 given AORT's growth acceleration."

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
• Barclays Downgrades HelloFresh SE (HFG:GR) (HLFFF) to Underweight